We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
SINNOWA MEDICAL SCIENCE & TECH

Download Mobile App





New COVID-19 Rapid Antigen Test Can Be Run on Mobile Testing Platform for Lab-Quality Test Results in 15 Minutes

By LabMedica International staff writers
Posted on 08 Jan 2021
Print article
Image: The Nanomix eLab® mobile testing platform (Photot courtesy of Nanōmix, Inc.)
Image: The Nanomix eLab® mobile testing platform (Photot courtesy of Nanōmix, Inc.)
A new COVID-19 rapid antigen test that provides lab-quality test results in 15 minutes could offer a frequent, fast, cheap and easy COVID-19 screening solution to help meet the surging demand for tests and relieve the global supply chain.

Nanōmix, Inc.’s (Emeryville, CA, USA) eLab COVID-19 Rapid Antigen test is a low-cost, easy-to-use, point-of-care test that provides results in 15 minutes with lab-quality accuracy. The battery-powered, handheld device utilizes proprietary biosensor and microfluidics technologies to perform an electrochemical detection in a single-use, disposable cartridge. The Nanomix eLab is a mobile platform that can test multiple biomarkers using multiple detection methods from a single patient sample in laboratory or non-laboratory environments - so any location, including rural or remote, can have rapid, lab-quality tests for COVID-19 and a variety of other diseases and conditions. The Nanomix eLab is battery powered, portable, and easy-to-use by non-professionals in a variety of critical applications such as assisted living communities, skilled nursing facilities, emergency medical services, schools, businesses, and remote towns and villages.

The company’s eLab COVID-19 assay has also been selected as a finalist in the XPRIZE Rapid COVID Testing competition. The USD 5 million, six-month competition aims to increase COVID-19 testing capabilities 100-times past the current standard, the level of increase needed to more safely return to everyday activities.

“We are excited to be selected as a finalist in the XPRIZE Rapid COVID Testing,” said David Ludvigson, CEO of Nanomix. “The goals of the competition – to develop frequent, fast, low-cost, and easy-to-use COVID tests – align with our corporate mission. The eLab Rapid COVID Antigen test, together with our eLab Rapid COVID Antibody test, form a complete offering for COVID-19 testing.”

“Fast, affordable, and accessible testing is crucial to containing the COVID-19 pandemic and safely reopening schools, businesses and other vital institutions around the world,” said Anousheh Ansari, CEO of XPRIZE. “XPRIZE Rapid COVID Testing competition is inspiring the best entrepreneurs and scientists to form teams and come together to work towards rapid, affordable COVID-19 testing at scale, and ultimately, getting the world up and running again.”

Related Links:
Nanōmix, Inc.


Print article

Channels

Molecular Diagnostics

view channel
Image: FIT (Fecal Immunochemical Test) is a stool test designed to identify possible signs of bowel disease. It detects minute amounts of blood in feces (fecal occult blood) (Photo courtesy of Alpha Laboratories, United Kingdom)

Study Confirms Performance of Rapid Stool Test for Detection of Colorectal Cancer

A recently published paper confirmed the diagnostic performance of the fecal immunochemical test (FIT) for patients with low-risk symptoms of colorectal cancer. The FIT uses specific antibodies to detect... Read more

Pathology

view channel
Image: The Leica Bond III stainer is fully automated Immunohistochemical and In Situ Hybridization (IHC and ISH stainer) (Photo courtesy of Leica Biosystems).

Mismatch Repair/Microsatellite Instability Evaluated Using Cytology Effusion Specimens

DNA mismatch repair (MMR) status is routinely assessed in colorectal and endometrial carcinoma as a method of cancer prevention, surveillance in patients with Lynch syndrome and their families, and for... Read more

Industry

view channel
Illustration

Roche Renews Partnership with Sysmex to Deliver Hematology Testing Solutions

Under the new framework of a Global Business Partnership Agreement (GBP) signed between Roche (Basel, Switzerland) and Sysmex Corporation (Kobe, Japan), both the companies have renewed their commitment... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.